Bispecific Antibodies Market is estimated to be US$ 915.4 million by 2030 with a CAGR of 6.6% during the forecast period

Download Sample

Published Date: May 2023

The Bispecific Antibodies Market accounted for US$ 484.9 million in 2019 and is estimated to be US$ 915.4 million by 2029 and is anticipated to register a CAGR of 6.6%. Bispecific antibody (BsAb) is an artificial protein that is made up of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the major application for the bispecific antibodies. These antibodies simultaneously bind to cytotoxic cell and target tumor cell and destroy it. Due to its dual specificity, these antibodies can block two different signaling pathways and redirect the T cells to tumor cells.

The report " Global Bispecific Antibodies Market, By Type (Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597), By Application (BsMAb for Cancer Diagnostic, BsMAb for Diagnosis of Bacterial & Infectious Diseases, BsAbs Blocking Signaling Pathways, BsAbs Targeting Tumor Angiogenesis, and Others), By End-User (Hospitals, Clinics and Research Centers) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

Key Highlights:

In Aug 2018, UCB Pharma, a scientific research company based in Belgium, conducted research on the molecule factors in bispecific antibody multimerisation and resulted as single-chain variable fragment containing bispecific antibody has monomer level and this level can be increased by conversion of single-chain variable fragment to a disulfide-stabilized single-chain variable fragment.
In Sept 2018, researcher from China Pharmaceutical University constructed and expressed a fully human bispecific single-chain diabody that can bind to vascular endothelial growth factor 165 (VEGF165) and programmed death-1 in Pichia pastoris.

Analyst View:

Increasing incidence of cancers is the major growth driver of global bispecific antibodies market. Many key players are coming with new drugs and new technologies. Various organizations such as W.H.O., FEAT, and others along with the government are spreading awareness about this condition which is anticipated to facilitate market growth in the forecast period.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Bispecific Antibodies Market, By Type (Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597), By Application (BsMAb for Cancer Diagnostic, BsMAb for Diagnosis of Bacterial & Infectious Diseases, BsAbs Blocking Signaling Pathways, BsAbs Targeting Tumor Angiogenesis, and Others), By End-User (Hospitals, Clinics and Research Centers) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

Key Market Insights from the report:

The Global Bispecific Antibodies Market accounted for US$ 484.9 million in 2019 and is estimated to be US$ 915.4 million by 2029 and is anticipated to register a CAGR of 6.6%. The Global Bispecific Antibodies Market is segmented based on the product, severity, application, and region.

On the basis of type, the Global Bispecific Antibodies Market is segmented into Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597.
On the basis of application, the target market is segmented into BsMAb for Cancer Diagnostic, BsMAb for Diagnosis of Bacterial & Infectious Diseases, BsAbs Blocking Signaling Pathways, BsAbs Targeting Tumor Angiogenesis, and Others.
On the basis of end-user, the target market is segmented into hospitals, clinics and research centers.
By region, the Global Bispecific Antibodies Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the worldwide leader in the bispecific antibodies market in terms of revenue, due to the developed healthcare system and health awareness among people.

Competitive Landscape:

The key players operating in the Global Bispecific Antibodies Market include Aspen Holdings, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, GlaxoSmithKline plc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Pfizer, Inc, Portola Pharmaceuticals, Inc., Sanofi S.A. and Others.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Some Important Points Answered in this Market Report Are Given Below:

Explains an overview of the product portfolio, including product development, planning, and positioning
Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
Detailed analysis of the market revenue over the forecasted period.
Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.
Study on the segments that are anticipated to dominate the market.
Study on the regional analysis that is expected to register the highest growth over the forecast period